Lenalidomide 10mg

Lenalidomide is the first representative of IMiDs, which has been authorized by the European Medicines Agency (EMA) for use in the treatment of tumors. The substance has been approved, in particular, in the European Union, Switzerland and the United States for use in combination therapy with dexamethasone in patients with multiple myeloma after previous therapy.

How does Lenalidomide 10 mg work?

The mechanism of action of Lenalidomide is multilevel, and at the molecular level has not yet been fully studied. However, the following mechanisms of action of the substance are mainly known:
1. Direct effect on tumor cells: arrest of growth and activation of “programmed cell death” (antiproliferative action).
2. Suppression of the release of inflammatory and oncogenic substances, including the difficulty of attaching tumor cells to the cells of the connective tissue of the bone marrow (the so-called stromal cells), as well as an increase in the release of tumor-suppressing signaling substances (tumor-toxic cytokines).
3. Suppression of vascular proliferation (anti-angiogenesis): the provision of tumor cells with nutrients deteriorates.
4. Activation of immune cells (T-cells and natural killer cells), which for their part attack tumor cells.

How should Lenalidomide 10 mg be taken?

Depending on the treatment plan, Lenalidomide in solid capsules is taken orally. Capsules cannot be opened or chewed. The medicinal preparation
That with anybody it is impossible to share, even if the person has the same symptoms. Only a doctor has the right to prescribe Lenalidomide 10 mg.

For multiple myeloma, the following dosage is recommended:

One-time reception on days 1-21 of repeated 28-day cycles. The recommended initial dose for normal liver function is 25 mg once a day, orally.
For patients with a new diagnosis of multiple myeloma, the recommended dose of dexamethasone is 40 mg once a day orally, on days 1, 8, 15 and 22 of each 28-day cycle.

When using Lenalidomide 10 mg one should pay attention to the following important aspects. When taking Lenalidomide during pregnancy, one should expect a teratogenic effect (impaired development of the fetus). Women of childbearing age, as well as men who have sexual intercourse with women of childbearing age, URGENTLY it is recommended to observe the program of protection from unwanted pregnancy.

Multiple myeloma remains, as before, an incurable disease, but it responds well to therapy, especially when it is diagnosed in time. Even with Lenalidomide treatment, diseased cells will never completely be removed from the body. In order to keep the further development of the disease as long as possible, taking Lenalidomide should be carried out regularly and for as long as it was prescribed by your doctor. If possible side effects strongly bother you, or you feel the need to stop treatment, it is NECESSARY to discuss this with your doctor. Only he can assess how this will affect the success of your treatment, and can help appropriate measures to alleviate the side effects. The safety and efficacy of Lenalidomide 10 mg have been proven in studies conducted to register and approve the use of this remedy. As a result of subsequent studies in February 2015, Lenalidomide, in combination with dexamethasone or in combination with Melphalan and prednisone, was allowed to treat patients with a new diagnosis of multiple myeloma not eligible for transplantation.